Physician profile
Khalid Malik
NPI 1407880305
$16,335.27
in general payments reported to CMS, 2019-2025
17 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.93 · 2020: $1,290 · 2021: $3,497 · 2022: $6,034 · 2023: $4,076 · 2024: $36.15 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,050 · Food and Beverage: $1,355 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,050.00 |
| Food and Beverage | $1,355.07 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,060.38 | 2021-2025 | |
| Allergan, INC. | $2,132.04 | 2020-2022 | |
| Lundbeck LLC | $236.02 | 2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $218.71 | 2025 | |
| Genentech USA, INC. | $169.71 | 2019-2025 | Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $89.17 | 2025 | Ajovy |
| Eisai INC. | $88.28 | 2025 | |
| Axsome Therapeutics, INC. | $72.45 | 2025 | Symbravo |
| Mdd US Operations, LLC | $59.12 | 2024-2025 | Gocovri |
| Biogen, INC. | $48.96 | 2025 | Skyclarys, Vumerity |
| Ucb, INC. | $28.36 | 2025 | Rystiggo |
| Sk Life Science, INC. | $28.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.72 | 2019-2022 | |
| Life Molecular Imaging Ltd | $22.83 | 2025 | Neuraceq |
| Pfizer INC. | $21.70 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.00 | 2025 | Rexulti |
| Lilly USA, LLC | $15.66 | 2025 | Kisunla, Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.